Facial Erythema of Rosacea: Grading Scales
Rosacea is a common condition characterized by centrofacial cutaneous features. Diagnosis is clinical and requires the presence of one of centrofacial erythema or phyma or two of the major criteria, which include flushing, papules/pustules, telangiectasia, and ocular manifestations. Assessment of facial erythema is of importance given its prevalence as the most common diagnostic feature of rosacea. Both physician-reported and patient-reported measures for assessing facial erythema of rosacea were developed during trials for brimonidine gel and subsequently tested for validity and reliability. The physician-reported measure was named the clinician erythema assessment (CEA), while the patient-reported measure was named the patient self-assessment (PSA). A variant of the PSA, termed the subject self-assessment (SSA), has also been created and used in subsequent clinical trials.
KeywordsRosacea Erythema PSA CEA SSA Grading Scale Validation
- Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633–41.CrossRefGoogle Scholar
- Stein-Gold L, Kircik LH, Draelos ZD, Werschler P, DuBois J, Lain E, et al. Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with Rosacea: findings from the Two phase 3, 29-day, randomized, controlled REVEAL trials. J Am Acad Dermatol. 2018; https://doi.org/10.1016/j.jaad.2018.01.028. [cited 2018 Mar 20]; [Epub ahead of print].